Rhode Island Medicaid spending on GLP-1 drugs

How much did Rhode Island Medicaid spend on GLP-1 drugs like Ozempic and Mounjaro in 2025?

Pharmacies were reimbursed at least $48.9 million for GLP-1 drugs paid through Rhode Island Medicaid in 2025, across at least 46,691 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 81 rows of 250, so these figures are floors.

Pharmacies were reimbursed at least $13.3 million for GLP-1 drugs paid through Rhode Island Medicaid in 2026 (quarter 1 only, as posted so far), across at least 12,340 prescriptions, according to CMS’s State Drug Utilization Data. That is the total amount reimbursed, federal and state shares together, before the rebates manufacturers pay states. CMS suppressed 23 rows of 69, so these figures are floors.

By year and ingredient

2020at least $367,988No dataat least $1,207,765at least $5,463,804at least $65,970at least $8,250at least $8,970No dataat least $7,122,746
2021at least $1,836,329No dataat least $1,360,839at least $8,274,507at least $62,320SuppressedSuppressedNo dataat least $11,533,995
2022at least $5,453,235at least $92,896at least $1,959,762at least $12,482,586at least $30,270SuppressedSuppressedSuppressedat least $20,018,750
2023at least $13,149,504at least $872,662at least $1,501,795at least $15,660,755SuppressedNo dataSuppressedSuppressedat least $31,184,716
2024at least $23,824,032at least $5,542,295at least $379,536at least $7,073,090SuppressedNo dataat least $9,452Suppressedat least $36,828,406
2025at least $31,272,026at least $13,369,656at least $303,416at least $3,943,656No dataNo dataSuppressedSuppressedat least $48,888,755
2026 (Q1)at least $7,901,190at least $4,916,853at least $32,778$477,378No dataNo dataSuppressedNo dataat least $13,328,198

By product, 2025

Ozempic$21,020,59321,4890 of 24
Rybelsusat least $1,256,363at least 1,29112 of 24
Wegovyat least $8,995,070at least 6,8993 of 40
Mounjaroat least $7,438,099at least 6,95119 of 48
Zepboundat least $5,931,557at least 5,63621 of 46
Liraglutide (generic name listing)at least $123,048at least 19711 of 20
Saxendaat least $180,369at least 1561 of 4
VictozaSuppressedSuppressed4 of 4
Trulicityat least $3,943,656at least 4,0722 of 32
SoliquaSuppressedSuppressed5 of 5
XultophySuppressedSuppressed3 of 3

By quarter, 2025

Q1 2025at least $10,881,480at least 10,46519 of 59
Q2 2025at least $12,507,209at least 12,03921 of 62
Q3 2025at least $12,651,804at least 12,05121 of 64
Q4 2025at least $12,848,262at least 12,13620 of 65

By quarter, 2026 (posted so far)

Q1 2026at least $13,328,198at least 12,34023 of 69

The amounts are CMS’s “Total Amount Reimbursed” field. CMS’s data dictionary for State Drug Utilization Data says of it:

“This total is not reduced or affected by Medicaid rebates paid to the state. This amount represents both the Federal and State Reimbursement and is inclusive of dispensing fees.”

Its prescription count is “The number of prescriptions reimbursed (by the Medicaid Program ONLY) to pharmacists for the (11-digit NDC) drug for the period covered.”

CMS suppresses some rows (its “Suppression Used” field is true and the counts and amounts are left blank). Here a suppressed row is never counted as zero: a figure that includes suppressed rows is shown as “at least” the sum of the rows CMS did publish, and a figure where every row is suppressed is shown as “Suppressed.” The “Rows suppressed” column gives the count. Where many rows are suppressed, the published sum can be well below the full amount, so floors for different states are not directly comparable.

Fee-for-service and managed care rows are added together. Other states: Medicare and Medicaid spending on GLP-1 drugs.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.